Companies developing new biological entities are challenged with daily uncertain outcomes and RISK management.
Celonic, with a pioneering spirit and an innovative portfolio, offers comprehensive approaches to not only mitigate the risk but also leverage deep industry insight to enable our clients to achieve commercial success.
Is your biopharmaceutical company developing new biological entities (NBE) and is thinking about launching or out-licensing a new biopharmaceutical product?
We minimise the risks in biopharmaceutical and process development because we think far into the future, plan carefully and offer attractive price models. There are no hidden licensing or other costs. You are aiming to develop a new biopharmaceutical product or a new production process? That is what our work is all about.